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Abstract
Background: N-acetyltransferase type 2 (Nat2) is a phase II drug- metabolizing enzyme that plays a key role in the
bioactivation of aromatic and heterocyclic amines. Its relevance in drug metabolism and disease susceptibility
remains a central theme for pharmacogenetic research, mainly because of its genetic variability among human
populations. In fact, the evolutionary and ethnic-specific SNPs on the NAT2 gene remain a focus for the potential
discoveries in personalized drug therapy and genetic markers of diseases. Despite the wide characterization of
NAT2 SNPs frequency in established ethnic groups, little data are available for highly admixed populations. In this
context, five common NAT2 SNPs (G191A, C481T, G590A, A803G and G857A) were investigated in a highly admixed
population comprised of Afro-Brazilians, Whites, and Amerindians in northeastern Brazil. Thus, we sought to
determine whether the distribution of NAT2 polymorphism is different among these three ethnic groups.
Results: Overall, there were no statistically significant differences in the distribution of NAT2 polymorphism when
Afro-Brazilian and White groups were compared. Even the allele frequency of 191A, relatively common in African
descendents, was not different between the Afro-Brazilian and White groups. However, allele and genotype
frequencies of G590A were significantly higher in the Amerindian group than either in the Afro-Brazilian or White
groups. Interestingly, a haplotype block between G590A and A803G was verified exclusively among Amerindians.
Conclusions: Our results indicate that ethnic admixture might contribute to a particular pattern of genetic
diversity in the NAT2 gene and also offer new insights for the investigation of possible new NAT2 gene-
environment effects in admixed populations.
Background
Genetic functional polymorphisms of xenobiotic/drug
metabolizing enzymes have been associated with phar-
macotherapy response differences and disease risk sus-
ceptibility [1,2]. Special emphasis has been placed on a
phase II metabolizing enzyme, N-acetyltransferase type
2 (Nat2, EC 2.3.1.5), a milestone in the pharmacoge-
netics field as one of the first enzymes to be associated
as a cause of interindividual variation in drug metabo-
lism [3]. Nat2 catalyzes a transfer of an acetyl group
from the cofactor acetyl-coenzyme A (acetyl-CoA) to
the amine nitrogen atom of aromatic amines and hydra-
zines [4]. This enzyme is important in the aromatic and
heterocyclic amine conjugating reaction, preventing
their metabolic activation into electrophilic intermedi-
ates that could initiate DNA damage and potentially
induce carcinogenic mutations [5]. Moreover, Nat2
plays a role in the metabolism of different hydrazine
and arylamine drugs, such as isoniazid and dapsone,
both used in the treatment of Mycobacterium spp. infec-
tions [6,7].
The human NAT2 gene has an intronless open read-
ing frame of 870 base pairs and is primarily expressed
in the liver and intestines [8-10]. It has long been recog-
nized that some single nucleotide polymorphisms
(SNPs) in the NAT2 gene may change protein structure
and/or stability and segregate in humans into “rapid”,
“intermediate” and “slow” acetylation phenotypes
[11,12]. The effects of genetic polymorphism in the
NAT2 gene on N-acetylation activity led to investiga-
tions of NAT2 SNPs as a promising genetic marker for
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disease risk, drug response therapy and/or adverse reac-
tions to drugs [13]. For example, slow acetylators are at
increased risk of peripheral neuropathies and systemic
lupus erythematosus due to hepatotoxicity to isoniazid
treatment, hypersensibility reactions to sulphonamides
and poor tolerance to sulfasalazine and dapsone [14].
Conversely, some authors demonstrated increased risk
of myelotoxicity induced by amonafide in rapid acetyla-
tors, probably due to the production of higher levels of
toxic metabolites from drugs [15].
If genetic factors underlie disease risk, the distribution
of susceptibility alleles may be influenced by ethnic
diversity [16]. Consistent with this question, several stu-
dies have shown that frequencies of NAT2 SNPs differ
among established ethnic groups [17]. Although the
characterization of the frequency of NAT2 SNPs has
been established in some ethnic groups, it is still neces-
sary to investigate the distribution of NAT2 SNPs in
populations characterized by a high degree of admixture.
Brazilian populations are of particular interest since it
was historically originated by Caucasian settlers, descen-
dents of African slaves, and by Amerindians [18-20]. In
this context, we investigated the frequency of five com-
mon NAT2 SNPs (G191A, C481T, G590A, A803G and
G857A; G191A) and haplotype structure in a highly
admixed population in Northeastern Brazil.
Methods
Subjects
All 183 individuals included in the current study were
residents in the Ilhéus area, healthy blood donors at São
José Hospital (Ilhéus, Bahia, Brazil) and reported at least
3 familial generations resident in Northeastern Brazil.
Volunteers were randomly selected during a 6-month
period and classified by self-reported ancestry into Afro-
Brazilian, Amerindians (native Brazilian descendents of
the Tupinamba tribe) or White. The Human Ethical
Committee of Universidade Estadual de Santa Cruz
approved the study and all volunteers gave their
informed consent.
Sample collection and genotyping
Peripheral blood was collected and genomic DNA isola-
tion was performed from white blood cells using the
FlexiGene DNA Kit (Qiagen, Boston, USA). NAT2 geno-
types were determined using a modification of a poly-
merase chain reaction (PCR)-restriction fragment length
polymorphisms (RFLP) assay [21]. Genomic DNA (100
ng) amplification was carried out in a 25 μL-reaction
volume containing 10 mmolL-1 Tris-HCl (pH 8.3), 50
mmolL-1 KCl, 1.5 mmolL-1 MgCl2, 0.2 mmolL
-1 of each
deoxynucleotide triphosphate (dNTP), 0.2 μmolL-1 of
each oligonucleotide primer (Forward, 5′-GGCTATAA-
GAACTCTAGGAAC-3′ and Reverse, 5′-AAGGGTT
TATTTTGTTCCTTATTCTAAAT-3′), and 1.25U of
Platinum Taq DNA polymerase (Invitrogen, California,
USA). Thermal cycling conditions for the PCR were as
follows: 5 min at 94°C, followed by 35 cycles of 94°C for
1 min, 55°C for 1 min, and 72°C for 1 min, with a final
extension at 72°C for 5 min.
Following amplification, genotyping was performed
using a RFLP assay to detect five different NAT2
SNPs: G191A (rs1801279), C481T (rs1799929), G590A
(rs1799930), A803G (rs1208) and G857A (rs1799931). In
this assay, PCR products (895 bp) were digested sepa-
rately with MspI, KpnI, TaqI, BamHI (Fermentas,
Canada) and DdeI (New England Biolabs, USA) to
detect a specific SNP (Table 1). All digestions were per-
formed according to the manufacturer’s recommenda-
tions. Digested PCR products were separated by
electrophoresis on 2% agarose gels (Pronadisa, Madrid,
Spain) for MspI, KpnI and BamHI or 10% polyacryla-
mide gels for TaqI and DdeI (90-100 V for 120 min or
6 hours, respectively) with DNA molecular size markers
(Invitrogen, California, USA). The amplified products
were visualized with ethidium bromide staining under
UV light.
Statistical analysis
Individual marker analysis comparing genetic and allelic
frequencies among ethnic groups was performed using
c2 tests. Multiple logistic regression analysis to evaluate
ethnic influences on the polymorphism frequency and
genetic associations were carried out using the Statistical
Package for the Social Sciences v.15.0 (Chicago, IL,
USA) and UNPHASED v.3.0.13 [22], respectively. We
used default settings of HAPLOVIEW v.4.1 software
[23] to evaluate pairwise linkage disequilibrium (LD)
between the five SNPs, genotype deviation from Hardy-
Weinberg equilibrium (HWE) and for association
between haplotypes defined by block in comparison
groups [23]. For an accurate type I error, we performed
1,000 permutations in each procedure test to estimate
the global significance of the observed differences. The
test computes the significance by counting the number
of ways the data can be permuted to determine how
unusual an observed outcome is. All tests were two-
tailed and the p level of significance retained was 0.05.
Results
Allelic and Genotypic Associations
The sample was composed predominantly of Afro-
Brazilians (68.31%), Whites (15.3%) and Amerindians
(16.39%) (average age 34.3 ± 10.2 yrs, 71% males).
The allele and genotype frequencies of the NAT2
SNPs obtained from all individuals and in separate
ethnic groups are summarized in Table 2. 481T was the
most frequent allele with 38.79% in the general
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population (33.9 - 43.3%) whereas the 191A allele was
less frequent in the three ethnic groups ranging from
5.0 and 10.7% (8.8% in total). No statistically significant
differences were observed in the distribution of NAT2
polymorphisms when comparing Afro-Brazilian and
White groups (Table 2). However, allelic and genotypic
frequencies of G590A polymorphism were significantly
increased in Amerindians when compared with other
ethnic groups and remained statistically different after
multiple testing corrections (Table 2), and multiple
Table 1 NAT2 SNPs used in this study
SNPs RFLP Enzyme Aminoacid Substitution Enzymatic Activity Reference
G191A
(rs1801279)
MspI Arg64Gln Reduced [28,29]
C481T
(rs1799929)
KpnI - Non-Altered [28]
G590A
(rs1799930)
TaqI Arg197Gln Reduced [28]
A803G
(rs1208)
DdeI Lys268Arg Non-Altered [26]
G857A*
(rs1799931)
BamHI Gly286Gln Reduced [28,30,31]
These levels are referents to the presence of a single SNP and If there is not anyone SNP in the 2 gene copies. *Substrate dependent.
Table 2 Genotypic and allelic frequency of NAT2 gene in different ethnic groups
NAT2
SNP Total Afro-Brazilians c
2 p1 Whites c2 p2 Amerindians c2 p3
G191A
GG 158 104 23 27
GA 22 20 1.075 0.5842 4 1.781 0.4104 3 1.207 0.547
AA 3 1 1 0
G 28 228 0.202 0.6593 50 1.322 0.2471 57 0.942 0.3061
A 338 22 6 3
C481T
CC 72 41 11 12
CT 79 60 2.565 0.2774 15 4.836 0.089 10 2.36 0.3073
TT 31 23 2 8
C 223 142 1.466 0.2221 37 1.079 0.2982 34 0.007 0.9338
T 141 106 19 26
G590A
GG 92 77 19 10
GA 67 46 1.298 0.5224 8 4.312 0.1158 14 9.943 0.0069b
AA 24 2 1 6
G 251 200 0.005 0.9405 46 4.661 0.0288a 34 8.4 0.0053c
A 115 50 10 26
A803G
AA 107 64 15 17
AG 73 61 3.662 0.1603 11 1.333 0.5135 12 0.954 0.6207
GG 3 0 2 1
A 287 189 1.686 0.1836 41 0.117 0.7316 46 0.834 0.3538
G 79 61 15 14
G857A
GG 129 86 17 24
GA 51 33 0.986 0.6108 10 3.391 0.1835 6 3.244 0.1975
AA 3 6 1 0
G 309 205 0.419 0.524 44 2.750 0.0964 54 2.013 0.1373
A 57 45 12 6
p: Genotype and allelic p-value for each marker, respectively. p1, p2 and p3: Association between Afro-Brazilians × Whites; Whites × Amerindians and Amerindians
× Afro-Brazilians, respectively. a, b and c: p-value adjusted (103 permutations) = 0.06494, 0.006993 and 0.004995, respectively. cχ2: Chi-square tests. Significant
association is indicated in bold.
Talbot et al. BMC Genetics 2010, 11:87
http://www.biomedcentral.com/1471-2156/11/87
Page 3 of 7
logistic regression analysis (OR = 3.714; 95%CI = 0.28-
8.54; p = 0.040) (Table 3). Although homozygous car-
riers of the A803G mutant allele (GG) were not detected
in Afro-Brazilian individuals in this study, this genotype
was found in the White and Amerindian descendents
with a frequency of 6.1 and 3.4%, respectively. Similarly,
homozygous carriers of G857A wild allele (AA) were
not found in the Amerindian group.
Haplotypic Associations
The sample was in Hardy-Weinberg equilibrium (p >
0.05) for the five SNPs (Table 4), as well as separately
by ethnicity (data not shown). NAT2 SNP combinations
were inferred from haplotype data. Linkage disequili-
brium (LD) analysis in the general population revealed
that the five common NAT2 SNPs had the weak D’ as
well as some low r2 values. Haplotype blocks were con-
structed if D’ between SNPs was 1.0. Using this criter-
ion, significant differences in haplotype structure among
the ethnic groups were observed (Figure 1).
Additionally to the haplotype analysis according to LD
pattern, another haplotype construction based on acety-
lator phenotype was performed using the most common
NAT2 slow SNPs. Thus, this approach estimates a mini-
mum percentage of slow acetylators and avoids misclas-
sification of NAT2 haplotypes in accordance with official
nomenclature. The G191A SNP, which leads to an
amino acid change in position 64 of the Nat2 protein,
produces an enzyme with reduced acetylation capacity
[24,25]. The same functional phenomenon occurs with
the G590A allele. In this context, we estimated that any
haplotype comprising at least one of these alleles, 191A
and 590A, should be theoretically treated as a slow acet-
ylator. It is worthwhile to observe that the slow acetyla-
tor haplotypes are underestimated, since the 857A allele
may also generate the slow acetylator phenotype
(NAT2*7A and NAT2*7B) [26].
Using this criterion, the haplotype distribution is
demonstrated in Table 4. For practical purposes, the
haplotype distribution was labelled from A to L in a
Table 3 Logistic regression analysis for risk of NAT2 mutant allele carrier among ethnic groups
Afro-Brazilians
OR (CI 95%) p
1 Whites
OR (CI 95%) p
2 Amerindians
OR (CI 95%) p
3
191A 1.81 (0.50-6.54) 0.392 1.95 (0.42-9.08) 0.361 0.22 (0.28-1.76) 0.0003
481T 1.35 (0.59-3.06) 0.474 0.97 (0.33-2.78) 0.651 1.50 (0.25-8.71) 0.277
590A 0.33 (0.12-0.95) 0.317 0.27 (0.07-1.03) 0.056 3.71 (0.28-8.54) 0.040
803G 1.52 (0.67-3.47) 0.320 0.97 (0.33-2.82) 0.961 1.02 (0.35-2.98) 0.356
857A 1.73 (0.65-4.60) 0.273 2.56 (0.77-8.51) 0.126 0.39 (0.05-2.89) 0.003
Reference group is G191, C481, G590, A803 and G857, respectively. Odds Ratio (OR) and 95% Confidence Interval (CI) for each reference allele compared are
shown. p: p-value. p1, p2 and p3. Association between Afro-Brazilians × Whites; Whites × Amerindians and Amerindians × Afro-Brazilians, respectively. Significant
association is indicated in bold.
Table 4 NAT2 haplotypes frequency in Brazilian ethnic groups.









(0.524) Total Afro-Brazilians Whites Amerindians
A (NAT2*4) G C G A G 45 33 9 6
B (NAT2*C) G T G G G 35 6 4 3
C* (NAT2*6A/*6B) G C A A G 23 3 1 7
D (NAT2*11A/*11B) G T G A G 23 5 2 2
E (NAT2*6I/6J) G C A A A 11 2 1 -
F (NAT2*7A/*7B) G C G A A 9 1 3 -
G (NAT2*14A/*14B/*14H) A C G A G 8 1 1 -
H (NAT2*12) G C G G G 6 1 1 -
I** (NAT2*6E) G T A A G 5 - - 3
J (n.ds.) G T G A A 4 1 - 0
K (NAT2*12C+857A) G T G G A 4 1 - 1
L (NAT2*14C/*14I) A T G A G 3 - 1 -
Slow Acetylator Haplotype A N A N N 50 29+ 6+ 11+
HWpval: Hardy-Weinberg equilibrium p-value for the whole sample. * and ** significant difference in frequency between Amerindians and Afro-Brazilians (cχ2:
6.517; p = 0.0107 and cχ2: 5.539; p = 0.0186, respectively). C, E, G, I and L are slow acetylator haplotypes and are indicated in bold. ‘-’: Absent or with frequency
< 1%. ‘N’: any nucleotide. ‘+’: haplotypes with frequencies < 1% are included. C.N.: Consensus Human Arylamine N-Acetyltransferase Gene Nomenclature -http://
louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature; (n.d.s): SNP combination not described.
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sliding scale, correspondent to and in accordance with
the human NAT2 nomenclature. Five slow acetylator
haplotypes were found (C, E, I, J, and L), which were
higher in Amerindians (44.9%) than in Afro-Brazilians
and Whites (22.9% and 25.8%, respectively) (Table 4).
Interestingly, we found some haplotypes in Amerindians
that were not found in the other groups (data not
shown). The most frequent haplotype among Afro-Bra-
zilians and Whites was “A” (26.1 and 35.3%, respec-
tively), whereas C was the most frequent haplotype
among Amerindians (28.6%). Among all haplotypes,
only the distribution of “C” and “I” was statistically dif-
ferent between Amerindians and Afro-Brazilians (p =
0.0107 and p = 0.0186, respectively) (Table 4). These
two haplotypes are correspondent to NAT2*6 haplotype
subgroups, (“C” = NAT2*6B; “I” = NAT2 *6E).
Discussion
Ethnicity is an important variable that influences an
individual’s health in several ways, in particular increas-
ing risks for the development of chronic diseases and
unresponsiveness or adverse reactions to drug treatment
[27]. The influence of the ethnic component in the dis-
tribution of NAT2 genetic polymorphism is well estab-
lished. An example is the ethnic-specific 191A allele,
mainly identified in Africans (7-20%) and with lower fre-
quencies in Euro-Caucasian groups (less than 2%)
[28-31]. Another example is the 857A allele, mainly
identified in eastern Asians [32].
Following our initial purpose of investigating the fre-
quency of NAT2 SNPs in a Brazilian admixed popula-
tion, the five most common NAT2 SNPs known from
published research were selected. Except for C481T
SNP, which does not alter the Nat2 enzymatic function,
the other four SNPs are associated with slow acetylator
status and had high frequencies in our whole sample as
well as among ethnic groups (Table 1 and 2). Although
the 191A allele has been described as relatively common
in African populations but not in Caucasians, no signifi-
cant difference was observed between both groups in
this study (Table 2). Similar results were obtained for
G590A. The ethnic similarity in the distribution of
NAT2 SNPs observed in this study could be due to the
high degree of admixture between Afro-descendents and
Euro-Caucasian groups (mainly Portuguese settlers) that
has occurred in Brazil over the centuries since coloniza-
tion [33]. However, the bias from the self-reported
ancestry classification method can not be totally
excluded.
Interestingly, meaningful results from the distribution
of NAT2 alleles in Amerindian descendents were
observed. The 590A allele was significantly more fre-
quent in Amerindians (42.5%) than in White or Afro-
Brazilian descendents (19.4% and 20.0%, respectively),
even after permutation tests to decrease the risk of a
type I error (Table 2). Multiple logistic regression analy-
sis confirmed that Amerindians have the highest fre-
quency of the 590A allele with OR (odds ratio) of 3.714
Figure 1 LD block structure across NAT2 gene. The upper panel shows the location of 5 polymorphisms in NAT2 gene and lower panel
shows the output of Haploview. LD plot where in each square (with D’ values written within the box) represent a pairwise linkage
disequilibrium relationship between the two SNPs. Squares indicate statistically significant LD between the pair of SNPs as measured by the D’
statistic. Darker colours of grey indicate higher values of D’, up to a maximum of 1 and white squares indicate pairwise D’ values of <1 with no
statistically significant evidence of LD. The blocks generated under confidence interval algorithm of Haploview are marked. A: Afro-Brazilians,
B: Whites and C: Amerindians.
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(95% confidence interval - CI = 0.284-8.545; p = 0.040)
(Table 3). Significant difference in the distribution of
the 191A allele between Amerindians and other groups
was revealed by multiple logistic regression analysis, but
not in UNPHASED association. The difference in results
may be attributed to the small sample size of 191A car-
riers among Amerindians. Moreover, the frequency of
the 590A allele in Amerindians is higher than what has
been reported in studies with Amerindians from
Panama (0% and 3.7% in Ngawbe and Embera Amerin-
dians, respectively) [17,34]. Such unexpected frequency
may have originated by phylogeographical differences
among Amerindians populations in South-America, mis-
cegenation, and genetic drift.
Despite Fuselli et al. (2007) having found that the
NAT2 variants are homogeneously distributed across
native populations, the Amerindian sample studied here
showed a lower frequency of the 857A allele (10.3%; OR
= 0.391; CI= 0.053-2.898; p= 0.003) than those observed
in two other Amerindians groups (23.3% and 22.8%) [35]
(Table 3). To date, the frequency of the 857A allele
observed in this study is similar to Asian and Central
America Amerindian populations [17], which corrobo-
rates the hypothesis that native Americans descend from
people who migrated from Siberia thousands of years ago
and therefore share their genetic background [36,37].
To elicit further information about the relationship of
SNPs, a haplotype analysis was performed. Although pre-
vious studies have shown the efficiency of the PHASE
method, we relied on the work of Sabbagh and Darlu
(2005), which shows the effectiveness of the EM method
for NAT2 haplotype reconstruction and suggests that
there is no impact on phenotype prediction compared to
results given by PHASE analysis [38]. We observed signifi-
cant differences in the haplotype structure and frequency
among the descendents of the three ethnic groups (Figure
1 and Table 4). Using haplotype analysis based on LD
data, a haplotype block between G590A-A803G (Block 1;
Figure 1C) was detected in Amerindians but was not
found in the other two ethnic groups. This result may
help to explain the highest frequency of slow acetylation
haplotypes in Amerindians (Table 4). Consistent with the
hypothesis that Amerindians may not be under a high
selective pressure for fast metabolism, we have previously
reported different distribution patterns of GSTP1 low
activity polymorphism in this same Amerindian popula-
tion [39]. Different distributions found in Amerindians,
when compared with other groups, may be attributed to
their low degree of admixture despite the high degree of
miscegenation in the whole population. This occurs for
historical reasons related to the particular way Brazil was
colonized. In this way, the Amerindian group still main-
tains its socio-economic distinction that contributes to
low degrees of admixture.
Due to our limited sample size, we suggest a careful
matching of ethnicity for future larger genetic investiga-
tions. Except among the Amerindian descendents, our
results suggest that self reported ethnicity might not
have significant effects on the distribution of these
NAT2 genetic variants studied in the Brazilian popula-
tion. This data is relevant due to the classic role of Nat2
on isoniazid metabolism in tuberculosis treatment,
which still remains an important problem of public
health. In fact, several reports indicate that the acetyla-
tor status is associated with drug-induced hepatitis and
Mycobacterium-resistance [40,41]. Furthermore, as
observed in other phase II metabolizing enzyme poly-
morphisms, NAT2 genetic variants have been used as a
genetic marker in different diseases like bladder and
colon-rectal cancers (fast acetylator and slow acetylator,
respectively) [42,43].
Conclusions
Information gathered on the distribution of genetic
polymorphism in populations of different ethnic origins
remains essential to understand the interethnic differ-
ences in drug disposition and disease risk. This study
demonstrates that common distributions of NAT2 SNPs
are related with ethnic background in a Brazilian
admixed population. Hereafter, DNA sequencing for the
entire intron-exon organization of the NAT2 gene will
provide more detailed information about genetic diver-
sity and structure in this population. All these findings
offer new insights for the investigation of possible non-
described NAT2 gene-environment effects in admixed
populations.
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